{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=92",
    "query": {
      "intervention": "Dose Level 3",
      "page": 92
    },
    "page_size": 10
  },
  "pagination": {
    "page": 92,
    "page_size": 10,
    "total_count": 17850,
    "total_pages": 1785,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=93&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=91&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T02:53:45.465Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07594236",
      "title": "Phase 1 Study of C.001 in Retinal Degeneration",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Geographic Atrophy",
        "Stargardt Disease",
        "RPE-mediated Maculopathy",
        "Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cellio Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2026-04-07",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-20T02:53:45.465Z",
      "location_count": 3,
      "location_summary": "Beverly Hills, California • Palo Alto, California • Sacramento, California",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07594236"
    },
    {
      "nct_id": "NCT05957536",
      "title": "A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER-2 Positive Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "D3L-001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "D3 Bio (Wuxi) Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2023-09-19",
      "completion_date": "2028-12-19",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-11-20T02:53:45.465Z",
      "location_count": 4,
      "location_summary": "Stanford, California • Boston, Massachusetts • New York, New York + 1 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05957536"
    },
    {
      "nct_id": "NCT02793544",
      "title": "HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome (MDS)",
        "Chronic Lymphocytic Leukemia (CLL)",
        "Chemotherapy-sensitive Lymphoma",
        "Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma",
        "Acute Myelogenous Leukemia (AML)",
        "Acute Biphenotypic Leukemia (ABL)",
        "Acute Undifferentiated Leukemia (AUL)"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation (TBI) 200cGy on Day -1",
          "type": "RADIATION"
        },
        {
          "name": "Infusion of non-T-cell depleted bone marrow on Day 0",
          "type": "PROCEDURE"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide 50mg/kg/day IV on Days -2,-1",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide 50mg/kg/day IV on Days -5,-4",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1",
          "type": "RADIATION"
        },
        {
          "name": "Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "Pre-HCT Mesna on Days -6 and -5",
          "type": "DRUG"
        },
        {
          "name": "Pre-HCT Mesna on Days -2 and -1",
          "type": "DRUG"
        },
        {
          "name": "Pre-HCT Mesna on Days -5 and -4",
          "type": "DRUG"
        },
        {
          "name": "Post-HCT Mesna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Center for International Blood and Marrow Transplant Research",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "15 Years to 70 Years"
      },
      "enrollment_count": 80,
      "start_date": "2016-12",
      "completion_date": "2020-03",
      "has_results": true,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-11-20T02:53:45.465Z",
      "location_count": 11,
      "location_summary": "Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02793544"
    },
    {
      "nct_id": "NCT03099564",
      "title": "Pembrolizumab Plus Y90 Radioembolization in HCC Subjects",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Y90 radioembolization",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Ashwin Somasundaram",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2017-03-28",
      "completion_date": "2023-06",
      "has_results": false,
      "last_update_posted_date": "2023-02-06",
      "last_synced_at": "2026-11-20T02:53:45.465Z",
      "location_count": 3,
      "location_summary": "Indianapolis, Indiana • Chapel Hill, North Carolina • Seattle, Washington",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03099564"
    },
    {
      "nct_id": "NCT01081964",
      "title": "Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Community Acquired Pneumonia"
      ],
      "interventions": [
        {
          "name": "Zabofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Levofloxacin 500mg",
          "type": "DRUG"
        },
        {
          "name": "Zabofloxacin 400mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IASO Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2010-03",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2012-05-07",
      "last_synced_at": "2026-11-20T02:53:45.465Z",
      "location_count": 13,
      "location_summary": "Huntsville, Alabama • Toney, Alabama • Fort Myers, Florida + 10 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Toney",
          "state": "Alabama"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Eagle",
          "state": "Idaho"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01081964"
    },
    {
      "nct_id": "NCT03040999",
      "title": "Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Head and Neck Neoplasms"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Accelerated Fractionation (AFX) Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Standard Fractionation (SFX) Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 804,
      "start_date": "2017-04-05",
      "completion_date": "2024-08-21",
      "has_results": true,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-11-20T02:53:45.465Z",
      "location_count": 24,
      "location_summary": "Los Angeles, California • San Francisco, California • Santa Rosa, California + 21 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03040999"
    },
    {
      "nct_id": "NCT03446599",
      "title": "Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Vasoplegia",
        "Hypotension",
        "Coronary Artery Disease",
        "Cardiac Valve Disease"
      ],
      "interventions": [
        {
          "name": "Hydroxocobalamin",
          "type": "DRUG"
        },
        {
          "name": "Methylene Blue",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-11",
      "completion_date": "2020-06-30",
      "has_results": false,
      "last_update_posted_date": "2020-03-02",
      "last_synced_at": "2026-11-20T02:53:45.465Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03446599"
    },
    {
      "nct_id": "NCT03480763",
      "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Infections"
      ],
      "interventions": [
        {
          "name": "V114",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 13™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PNEUMOVAX™23",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 652,
      "start_date": "2018-06-22",
      "completion_date": "2019-12-23",
      "has_results": true,
      "last_update_posted_date": "2021-11-02",
      "last_synced_at": "2026-11-20T02:53:45.465Z",
      "location_count": 15,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Spring Valley, California + 12 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03480763"
    },
    {
      "nct_id": "NCT00908687",
      "title": "A/H5N1/LT Dose Ranging Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pandemic Influenza"
      ],
      "interventions": [
        {
          "name": "A/H5N1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LT Adjuvant Patch",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Intercell USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 500,
      "start_date": "2009-05",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2021-12-10",
      "last_synced_at": "2026-11-20T02:53:45.465Z",
      "location_count": 6,
      "location_summary": "Anaheim, California • Vallejo, California • Miami, Florida + 3 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "South Bend",
          "state": "Indiana"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00908687"
    },
    {
      "nct_id": "NCT07360314",
      "title": "Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "M7437",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2026-02-13",
      "completion_date": "2029-03-28",
      "has_results": false,
      "last_update_posted_date": "2026-11-13",
      "last_synced_at": "2026-11-20T02:53:45.465Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • Huntersville, North Carolina • Galveston, Texas + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        },
        {
          "city": "Galveston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07360314"
    }
  ]
}